Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
PSTX Poseida Therapeutics	$9.50	$9.48	$2.32 ▼ $9.67	$928.85M	1.63	998,123 shs	N/A
PTGX Protagonist Therapeutics	$56.37 +0.1%	$46.43	$30.67 ▼ $60.60	$3.49B	2.25	1.00 million shs	959,570 shs
RARE Ultragenyx Pharmaceutical	$37.49 -4.6%	$35.91	$29.59 ▼ $60.37	$3.54B	0.25	856,200 shs	1.09 million shs
SWTX SpringWorks Therapeutics	$46.78 +0.0%	$43.84	$28.21 ▼ $62.00	$3.52B	0.7	2.35 million shs	4.50 million shs

Metaverse Stocks And Why You Can't Ignore Them

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
PSTX Poseida Therapeutics	0.00%	0.00%	0.00%	0.00%	+239.29%
PTGX Protagonist Therapeutics	+1.77%	+4.65%	+27.22%	+2.81%	+65.79%
RARE Ultragenyx Pharmaceutical	+4.75%	+6.45%	+10.99%	-0.13%	-11.98%
SWTX SpringWorks Therapeutics	+0.02%	-0.09%	+1.17%	-8.56%	+20.39%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
PSTX Poseida Therapeutics	0.4818 of 5 stars	1.0	0.0	4.6	0.0	0.8	0.0
PTGX Protagonist Therapeutics	2.0106 of 5 stars	2.5	2.0	0.0	2.1	2.5	1.3
RARE Ultragenyx Pharmaceutical	4.4232 of 5 stars	3.5	3.0	3.8	3.9	2.5	0.6
SWTX SpringWorks Therapeutics	1.5872 of 5 stars	3.1	2.0	0.0	2.6	0.0	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
PSTX Poseida Therapeutics	2.00	Hold	$9.50	N/A
PTGX Protagonist Therapeutics	3.00	Buy	$65.44	16.10% Upside
RARE Ultragenyx Pharmaceutical	2.92	Moderate Buy	$88.77	136.78% Upside
SWTX SpringWorks Therapeutics	2.13	Hold	$52.57	12.38% Upside

Current Analyst Ratings Breakdown

Latest PSTX, SWTX, RARE, and PTGX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/3/2025	PTGX Protagonist Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$80.00
5/28/2025	RARE Ultragenyx Pharmaceutical	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$65.00
5/19/2025	PTGX Protagonist Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$80.00 ➝ $80.00
5/12/2025	SWTX SpringWorks Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral	$47.00 ➝ $47.00
5/9/2025	RARE Ultragenyx Pharmaceutical	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$64.00 ➝ $65.00
4/30/2025	SWTX SpringWorks Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Neutral	$74.00 ➝ $47.00
4/29/2025	SWTX SpringWorks Therapeutics	Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Hold
4/29/2025	SWTX SpringWorks Therapeutics	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Hold	$66.00 ➝ $47.00
4/28/2025	SWTX SpringWorks Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Neutral	$77.00 ➝ $47.00
4/28/2025	SWTX SpringWorks Therapeutics	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
4/28/2025	SWTX SpringWorks Therapeutics	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Equal Weight	$63.00 ➝ $47.00

(Data available from 6/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
PSTX Poseida Therapeutics	$150.86M	6.16	N/A	N/A	$1.08 per share	8.80
PTGX Protagonist Therapeutics	$207.80M	16.81	N/A	N/A	$5.84 per share	9.65
RARE Ultragenyx Pharmaceutical	$590.69M	6.00	N/A	N/A	$2.76 per share	13.58
SWTX SpringWorks Therapeutics	$219.67M	16.05	N/A	N/A	$10.01 per share	4.67

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
PSTX Poseida Therapeutics	-$123.43M	-$0.63	N/A	N/A	N/A	-40.28%	-72.26%	-21.53%	N/A
PTGX Protagonist Therapeutics	-$78.96M	$0.75	21.19	N/A	N/A	52.76%	34.68%	30.98%	8/5/2025 (Estimated)
RARE Ultragenyx Pharmaceutical	-$569.18M	-$5.88	N/A	N/A	N/A	-101.60%	-193.80%	-38.15%	7/30/2025 (Estimated)
SWTX SpringWorks Therapeutics	-$325.10M	-$3.41	N/A	N/A	N/A	-134.73%	-46.74%	-41.12%	8/6/2025 (Estimated)

Latest PSTX, SWTX, RARE, and PTGX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/9/2025	Q1 2025	SWTX SpringWorks Therapeutics	-$0.81	-$1.11	-$0.30	-$1.11	$64.19 million	$49.09 million
5/6/2025	Q1 2025	PTGX Protagonist Therapeutics	-$0.50	-$0.19	+$0.31	-$0.19	$30.44 million	$28.32 million
5/6/2025	Q1 2025	RARE Ultragenyx Pharmaceutical	-$1.54	-$1.57	-$0.03	-$1.57	$145.98 million	$139.29 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
PSTX Poseida Therapeutics	N/A	N/A	N/A	N/A	N/A
PTGX Protagonist Therapeutics	N/A	N/A	N/A	N/A	N/A
RARE Ultragenyx Pharmaceutical	N/A	N/A	N/A	N/A	N/A
SWTX SpringWorks Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
PSTX Poseida Therapeutics	0.68	3.20	3.20
PTGX Protagonist Therapeutics	N/A	10.69	10.70
RARE Ultragenyx Pharmaceutical	N/A	2.37	2.65
SWTX SpringWorks Therapeutics	N/A	6.16	6.02

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
PSTX Poseida Therapeutics	46.87%
PTGX Protagonist Therapeutics	98.63%
RARE Ultragenyx Pharmaceutical	97.67%
SWTX SpringWorks Therapeutics	N/A

Insider Ownership

Company	Insider Ownership
PSTX Poseida Therapeutics	2.90%
PTGX Protagonist Therapeutics	4.90%
RARE Ultragenyx Pharmaceutical	5.50%
SWTX SpringWorks Therapeutics	7.83%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
PSTX Poseida Therapeutics	260	97.77 million	94.94 million	Optionable
PTGX Protagonist Therapeutics	120	61.98 million	56.38 million	Optionable
RARE Ultragenyx Pharmaceutical	1,310	94.54 million	86.99 million	Optionable
SWTX SpringWorks Therapeutics	230	75.35 million	68.73 million	Optionable

PSTX, SWTX, RARE, and PTGX Headlines

Recent News About These Companies

SpringWorks Therapeutics (NASDAQ:SWTX) Sees Large Volume Increase - What's Next?

June 9, 2025 | marketbeat.com

SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) Shares Sold by Squarepoint Ops LLC

June 5, 2025 | marketbeat.com

RFG Advisory LLC Takes $3.93 Million Position in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX)

June 4, 2025 | marketbeat.com

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Acquires 19,315 Shares of SpringWorks Therapeutics, Inc. (NASDAQ:SWTX)

June 4, 2025 | marketbeat.com

SPRINGWORKS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of SpringWorks Therapeutics, Inc. - SWTX

June 3, 2025 | businesswire.com

Nuveen Asset Management LLC Has $6.64 Million Holdings in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX)

May 31, 2025 | marketbeat.com

BNP Paribas Financial Markets Makes New $351,000 Investment in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX)

May 28, 2025 | marketbeat.com

SpringWorks Therapeutics (SWTX) Surged on Acquisition News

May 27, 2025 | msn.com

SpringWorks Therapeutics’ SWOT analysis: biotech stock faces acquisition challenges

May 27, 2025 | investing.com

SpringWorks Gets CHMP Nod for Mirdametinib in Rare Disease

May 26, 2025 | zacks.com

ProShare Advisors LLC Has $827,000 Holdings in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX)

May 26, 2025 | marketbeat.com

Deutsche Bank AG Increases Position in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX)

May 25, 2025 | marketbeat.com

SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) Receives Consensus Recommendation of "Hold" from Analysts

May 25, 2025 | marketbeat.com

Palisades Investment Partners LLC Buys 12,154 Shares of SpringWorks Therapeutics, Inc. (NASDAQ:SWTX)

May 24, 2025 | marketbeat.com

SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) Shares Sold by Bank of America Corp DE

May 24, 2025 | marketbeat.com

SpringWorks gets EU endorsement for genetic disorder treatment

May 23, 2025 | msn.com

SpringWorks Therapeutics Receives Positive CHMP Opinion for Mirdametinib for the Treatment of Adult and Pediatric Patients with NF1-PN

May 23, 2025 | globenewswire.com

Woodline Partners LP Buys 108,512 Shares of SpringWorks Therapeutics, Inc. (NASDAQ:SWTX)

May 22, 2025 | marketbeat.com

Zimmer Partners LP Buys New Shares in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX)

May 22, 2025 | marketbeat.com

Velan Capital Investment Management LP Makes New $6.70 Million Investment in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX)

May 21, 2025 | marketbeat.com

Rafferty Asset Management LLC Has $4.44 Million Holdings in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX)

May 21, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

3 Defense Stocks That Will Profit From a Golden Dome
By Chris Markoch | May 30, 2025
View 3 Defense Stocks That Will Profit From a Golden Dome
Analysts Think These Stocks Could More Than Double in Value
By Nathan Reiff | May 23, 2025
View Analysts Think These Stocks Could More Than Double in Value
3 Stocks Getting Rare Double Upgrades From Analysts
By Chris Markoch | June 6, 2025
View 3 Stocks Getting Rare Double Upgrades From Analysts
Keep Your EYE on This Stock, It Just Got a Rare Double Upgrade
By Sam Quirke | May 15, 2025
View Keep Your EYE on This Stock, It Just Got a Rare Double Upgrade
Tesla Stock: Why These 2 Downgrades Are Actually a Buy Signal
By Sam Quirke | June 11, 2025
View Tesla Stock: Why These 2 Downgrades Are Actually a Buy Signal

PSTX, SWTX, RARE, and PTGX Company Descriptions

Poseida Therapeutics NASDAQ:PSTX

Poseida Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company's development candidates for Heme Malignancies includes P-BCMA-ALLO1, which is in Phase I trial to treat patients with relapsed/refractory multiple myeloma; P-CD19CD20-ALLO1, which is in Phase I trial for treating B cell malignancies and other autoimmune diseases; P-BCMACD19-ALLO1, an allogeneic, off-the-shelf CAR-T product candidate in preclinical development for treating multiple myeloma; and P-CD70-ALLO1 under preclinical development to treat hematological indications. It is also involved in the development of P-MUC1C-ALLO1 that is in Phase I trial for treating a range of solid tumors, including breast, colorectal, lung, ovarian, pancreatic, and renal cancers; P-PSMA-ALLO1, an autologous chimeric antigen receptor T cell (CAR-T) product candidate that is in preclinical development for the treatment of patients with metastatic castrate resistant prostate cancer (mCRPC); and P-PSMA-101, an allogeneic CAR-T product candidate under Phase 1 clinical trial for treating mCRPC. In addition, the company engages in the development of P-FVIII-101, a clinical stage liver-directed gene therapy for the in vivo treatment of hemophilia A; P-OTC-101, a clinical stage liver-directed gene therapy for the in vivo treatment of ornithine transcarbamylase deficiency; and P-PAH-101, a clinical stage liver-directed gene therapy for the in vivo treatment of phenylketonuria. It has a research collaboration and license agreement with F. Hoffmann-La Roche Ltd, and Hoffmann-La Roche Inc. The company was incorporated in 2014 and is headquartered in San Diego, California.

Protagonist Therapeutics NASDAQ:PTGX

$56.37 +0.05 (+0.09%)

Closing price 04:00 PM Eastern

Extended Trading

$56.40 +0.03 (+0.04%)

As of 04:08 PM Eastern

Protagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis. The company has a license and collaboration agreement with Takeda to commercialize rusfertide; and JNJ Innovative Medicines to co-develop Interleukin-23 receptor antagonist compound JNJ-2113. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.

Ultragenyx Pharmaceutical NASDAQ:RARE

$37.49 -1.80 (-4.58%)

Closing price 04:00 PM Eastern

Extended Trading

$37.50 +0.01 (+0.03%)

As of 04:38 PM Eastern

Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidatures include DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome; UX111, an AAV9 gene therapy product candidate for the treatment of patients with Sanfilippo syndrome type A, or MPS IIIA, a rare lysosomal storage disease; UX701, for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; Bayer Healthcare LLC; GeneTx; Mereo; University of Pennsylvania; Arcturus Therapeutics Holdings Inc.; Solid Biosciences Inc.; Regeneron; Abeona; and Daiichi Sankyo Co., Ltd. The company was incorporated in 2010 and is headquartered in Novato, California.

SpringWorks Therapeutics NASDAQ:SWTX

$46.78 +0.02 (+0.04%)

Closing price 04:00 PM Eastern

Extended Trading

$46.80 +0.02 (+0.03%)

As of 04:10 PM Eastern

SpringWorks Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is OGSIVEO (nirogacestat), an oral small molecule gamma secretase inhibitor that is in Phase III DeFi trial for the treatment of desmoid tumors; and Nirogacestat, is also in Phase 2 clinical development as a monotherapy for the treatment of ovarian granulosa cell tumors (GCT), a subtype of ovarian cancer. The company is also involved in the development of mirdametinib, an oral small molecule MEK inhibitor that is in Phase 2b clinical trials for the treatment of neurofibromatosis type 1-associated plexiform neurofibromas (NF1-PN); mirdametinib + lifirafenib, a combination therapy that is in Phase 1b clinical trial in patients with advanced or refractory solid tumors; and mirdametinib in monotherapy and combination approaches to treat other genetically defined solid tumors, including Phase 1/2 clinical trial for the treatment of pediatric and young adult patients with low-grade gliomas. In addition, it develops Brimarafenib (BGB-3245), an oral selective small molecule inhibitor of monomeric and dimeric forms of activating BRAF mutations. The company has collaborations with BeiGene, Ltd. and GlaxoSmithKline LLC; and license agreements with Pfizer Inc. for nirogacestat and mirdametinib. It also has a license agreement with Katholieke Universiteit Leuven and the Flanders Institute for Biotechnology for a portfolio of novel small molecule inhibitors of the TEA Domain; and Dana-Farber Cancer Institute for a portfolio of novel small molecule inhibitors of Epidermal Growth Factor Receptor. The company was founded in 2017 and is headquartered in Stamford, Connecticut.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time